Executive Summary
This Contract Deobligations Alert covers $259,112,045 in total obligations across three civilian contracts from NASA, HHS/BARDA, and the Department of State, with zero defense-related awards.
The dominant theme is long-duration civilian R&D and IT services, highlighted by Basilea Pharmaceutica International Ltd's $92.5M bullish BARDA award for antimicrobials R&D against resistant infections, offering the highest-conviction growth signal with potential upside to $267.6M ceiling through 2035. Neutral signals dominate from historical LJT & Associates' $94.6M NASA launch support contract (ended 2019 with minimal $8.8M outlay) and ongoing Idemia National Security Solutions LLC's $72M State Department facial recognition integration (partial $18.2M outlay to 2026). A key risk is low outlay pacing across all contracts, signaling potential deobligation or execution hurdles. Investors should watch BARDA option exercises for Basilea as the primary near-term catalyst amid civilian agency priorities.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Contract Deobligations Alert digest from April 28, 2026.
Investment Signals (3)
- Basilea Pharmaceutica International Ltd Secures $92.5M BARDA Cost-Sharing Contract for Antimicrobials R&D (HIGH)▲
HHS/BARDA awarded Basilea $92,501,232 (ceiling $267.6M with options) on 2024-09-18 for R&D on antimicrobials targeting resistant fungal and bacterial infections, with performance to 2031-09-30 (potential 2035-12-31) and $36.2M outlayed to date under full competition.
- LJT & Associates NASA Contract Shows Low $8.8M Outlay Against $94.6M Obligation (MEDIUM)▲
LJT & Associates' 2016 NASA Goddard contract for Wallops Island launch operations ended in 2019 with only $8,769,312 outlayed against $94,578,354 obligation and ceiling of $108.1M, indicating potential deobligation and limited ongoing revenue.
- Idemia National Security Solutions LLC $72M State Department Facial Recognition Delivery Order Ongoing (MEDIUM)▲
Department of State awarded Idemia $72,032,459 (ceiling $74.1M) in 2018 for facial recognition integration with visa/passport processes, with $18,176,969 outlayed through 2026-09-29 under firm fixed price.
Risk Flags (2)
- Execution [HIGH RISK]▼
Low outlay pacing on LJT & Associates' $94.6M NASA contract ($8.8M outlayed post-2019 end) and Idemia's $72M State contract ($18.2M outlayed over 8 years) signals potential deobligations or delays.
- Budget [MEDIUM RISK]▼
Basilea Pharmaceutica's $92.5M BARDA contract carries R&D execution risks with only $36.2M outlayed early in 7-year base period, vulnerable to milestone failures.
Opportunities (1)
- ◆
Basilea Pharmaceutica International Ltd's BARDA contract offers expansion from $92.5M obligation to $267.6M ceiling via options for antimicrobials R&D.
Sector Themes (2)
- ◆
Basilea's $92.5M cost-sharing award (NAICS 541714, PSC AN42) underscores BARDA's commitment to antimicrobials for resistant infections, with 7-11 year visibility.
- ◆
Idemia's $72M State facial recognition (PSC 7030) and LJT's historical $94.6M NASA launch ops (PSC AJ45) highlight ongoing but low-outlay civilian IT/security and space services.
Watch List (3)
- 👁
{"entity"=>"Basilea Pharmaceutica International Ltd", "reason"=>"$92.5M BARDA obligation with $267.6M ceiling; only $36.2M outlayed early in term", "trigger"=>"option exercises toward 2035-12-31; outlay progress beyond $36.2M"}
- 👁
{"entity"=>"LJT & Associates, Inc.", "reason"=>"$94.6M NASA obligation ended 2019 with $8.8M outlay; no follow-on visibility", "trigger"=>"follow-on contracts post-2019; deobligation confirmation"}
- 👁
{"entity"=>"Idemia National Security Solutions LLC", "reason"=>"$72M State obligation with $18.2M outlayed over 8 years to 2026", "trigger"=>"outlay acceleration; option exercises to $74.1M; 2026-09-29 re-compete"}
Get daily alerts with 3 investment signals, 2 risk alerts, 1 opportunities and full AI analysis of all 3 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Contract Deobligations Alert
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals